article thumbnail

Golgi Neurosciences Partners with CDD Vault to Drive Innovation in Neurodegenerative Disease Treatment

Collaborative Drug

a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.

article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog: Drug Discovery

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. The Natural History Studies Grants Program funds natural history studies that collect gather data on how rare diseases progress over time without treatment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A smartphone app for the self-management of Perthes’ Disease – a blog for Rare Disease Day 2024

On Medicine

The cause is unknown, and there is currently no evidence stating whether surgical or non-surgical treatment is best for children with Perthes’ disease. This is a commonly used method, particularly when there is not a wealth of evidence to direct treatment. What is the NON-STOP project?

Disease 109
article thumbnail

Drug Discovery Industry Roundup with Barry Bunin — December 18, 2023

Collaborative Drug

Discover the impact of 'junk DNA' on cancer, teen obesity treatments, Neanderthal genes on sleep patterns, and Nobel discoveries shaping medicine

DNA 298
article thumbnail

Buprenorphine now replaces methadone as the most common medicine for opioid dependence’: 10-year trends in opioid agonist treatment medicines in Australia

National Drug & Alcohol Research Centre Blog

Kendal Chidwick NDARC’s Kendal Chidwick discusses the findings from a recently published study that examined how patterns of opioid agonist treatment medicines have changed over the past decade. Other changes around this time aimed at improving treatment accessibility included increased use of take-home doses and telehealth appointments.

Treatment 133
article thumbnail

CRISPR in the Clinic

addgene Blog

In 2014, we wrote a blog post on CRISPR’s potential for correcting monogenetic diseases. Now, almost 10 years later, CRISPR’s potential for treatment is no longer an accurate descriptor; progress in clinical therapy is more fitting, so it is time to update our post.

Therapies 127
article thumbnail

Present Treatments & Hopeful Future Directions for ALS Pharmacotherapies

Conversations in Drug Development Trends

Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. The MAA file in the E.U.